Sarabjit Kour Nangra of Angel Broking shares her outlook on the road ahead for Infosys. Money Control, 3 weeks ago
Infosys: How analysts read Q1 numbers - MyIris, 3 weeks ago
Infosys Q1 beats forecast; recommends 'Buy': Angel Broking - MyIris, 3 weeks ago
2 images for "sarabjit kour nangra"
Sarabjit Kour Nangra VP Research- Pharma Angel Broking W The Nexium Generic is a bigger opportunity for Ranbaxy than Valcyte generic, she says in an interview with CNBC-TV18's Ekta Batra. Given the Sun-Ranbaxy merger, Nangra sees an upside ...Moneycontrol.com, 1 month ago Launch of generic diovan key opportunities for Ranbaxy: Angel Broking MyIris, 1 month ago
HCL Technologies posted numbers better than expected on OPM and net profit front, while top-line came in just in line with expectations. The company posted revenues of USD 1,407 million, up 3.4% qoq, in line with the expectation of USD 1,407.5 ...MyIris, 1 day ago
Shares of drug firm Lupin today rose by almost 5.5 per cent after it reported a 55.74 per cent jump in consolidated net profit for the quarter ended June 2014. Lupin's stock settled 4.90 per cent up at Rs 1,173.50 on the BSE. In intra-day session, ...Business Standard India, 2 days ago
Buoyed by a strong performance in its U.S. and Indian operations, pharmaceutical major Lupin reported a record performance in the quarter ended June 2014 with the net profit rising 56 per cent to Rs.624.7 crore. The company reported a net sales of ...The Hindu, 2 days ago
The pharmaceutical sector has been one of the highest sectoral gainers in recent weeks, with six of the top 10 stocks by market capitalisation touching their all-time highs in July. Expectations of a strong performance in the June quarter, ahead of the results announcement by top pharma companies this week, has been one reason for the price surge. In addition, consistent performance and preference of investors for stocks in the defensive space helped the sector outshine the broader markets. ...Rediff.com, 4 days ago
More from: , Smart Investor...and 1 other sources
Mumbai, July 27: GlaxoSmithKline Plc (GSK) is likely to receive a good response if it indeed puts up its older but off-patented drugs for sale, given the massive gain Bafna Pharma made from Raricap. According to reports, Lupin is eyeing some of the ...Calcutta Telegraph, 4 days ago
Mumbai : Ipca Laboratories said it has voluntarily stopped shipments to the US from its bulk drug manufacturing facility at Ratlam, Madhya Pradesh , after the Food and Drug Administration The letter outlined a half a dozen violations of standard ...4 Traders, 6 days ago Ipca halts shipments from Ratlam unit after FDA flags violations DNA India, 1 week ago After FDA concerns, Ipca halts drug shipment to US Financial Chronicle, 1 week ago 'Suspension of API shipments to US will impact IPCA's FY2015 sales' Hindu Business Line, 1 week ago
Wipro, India's third-biggest IT services exporter, reported 29 per cent growth in June quarter profit at Rs 2,118 crore compared with Rs 1,631 crore posted for the corresponding quarter last year. Total revenue stood at Rs 11,135 crore against Rs ...Financial Chronicle, 1 week ago UPDATE 2-India's Wipro sees strong sales growth, eyes Europe deals Reuters, 1 week ago Wipro sees strong sales growth, eyes Europe deals The Week, 1 week ago India's Wipro sees strong sales growth, eyes Europe deals Sharenet, 1 week ago
During the recent USFDA inspection at the IPCA Labs Active Pharmaceutical Ingredients(APls) manufacturing facility situated at Ratlam (Madhya Pradesh), the company has received certain inspection observations in Form 483 from the USFDA. Consequent ...MyIris, 1 week ago Ipca stops US shipments of products from Ratlam facility The Hindu, 1 week ago
on your WebpageAdd Widget >Get your members hooked!